RT Journal Article SR Electronic T1 Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 649 OP 654 DO 10.2967/jnumed.119.232827 VO 61 IS 5 A1 Chen, Aiping A1 Mokrane, Fatima-Zohra A1 Schwartz, Lawrence H. A1 Morschhauser, Franck A1 Stamatoullas, Apasia A1 Schiano de Colella, Jean-Marc A1 Vercellino, Laetitia A1 Casasnovas, Olivier A1 Chauchet, Adrien A1 Delmer, Alain A1 Nicolas-Virelizier, Emmanuelle A1 Ghesquières, Hervé A1 Moles-Moreau, Marie-Pierre A1 Schmitt, Anna A1 Dulery, Rémy A1 Bouabdallah, Krimo A1 Borel, Cecile A1 Touati, Mohamed A1 Deau-Fischer, Benedicte A1 Peyrade, Frédéric A1 Seban, Romain-David A1 Manson, Guillaume A1 Armand, Philippe A1 Houot, Roch A1 Dercle, Laurent YR 2020 UL http://jnm.snmjournals.org/content/61/5/649.abstract AB Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients with relapsed or refractory classic Hodgkin lymphoma (HL). To date, no prognostic factor for overall survival (OS) has been established with these agents in HL. We examined whether the first early response assessment evaluated using 18F-FDG PET/CT may be associated with OS in this setting. Methods: This retrospective study included 45 patients from 34 institutions. In a masked, centralized review, 3 independent radiologists classified PET/CT scans obtained at a median of 2.0 mo (interquartile range, 1.7–3.7 mo) after nivolumab initiation using existing criteria (i.e., 2014 Lugano classification and 2016 LYRIC). Patients were classified according to 4 possible response categories: complete metabolic response (CMR), partial metabolic response (PMR), no metabolic response (NMR), or progressive metabolic disease (PMD). Because the OS of patients with NMR and PMR was similar, they were grouped together. OS was estimated using the Kaplan–Meier method and compared between groups using log-rank testing. Results: Eleven patients (24%) died after a median follow-up of 21.2 mo. The classification was identical between Lugano and LYRIC because all 16 progression events classified as indeterminate response per LYRIC were confirmed on subsequent evaluations. Both Lugano and LYRIC classified patients as CMR in 13 cases (29%), PMD in 16 (36%), NMR in 4 (9%), and PMR in 12 (27%). The 2-y OS probability was significantly different in patients with PMD (0.53; 95% confidence interval [95%CI], 0.32–0.87), NMR or PMR (0.80; 95%CI, 0.63–1.00), and CMR (1.00; 95%CI, 1.00–1.00) in the overall population (P = 0.02, 45 patients), as well as according to a landmark analysis at 3 mo (P = 0.05, 32 patients). Conclusion: In relapsed or refractory HL patients treated with anti-PD-1 mAbs, the first early PET/CT assessment using either Lugano or LYRIC predicted OS and allowed early risk stratification, suggesting that PET/CT might be used to develop risk-adapted strategies.